Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04538794 · ClinicalTrials.gov registry record · Phase 1
A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
A Phase 1 study, sponsored by Celldex Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT04538794: Completed Phase 1 study, sponsored by Celldex Therapeutics.
NCT04538794 is a Phase 1 study that has completed, run by Celldex Therapeutics. The registered enrollment target is 45 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04538794, a Phase 1 study, has completed, sponsored by Celldex Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This is a study to determine the safety of multiple doses of CDX-0159 in patients with Chronic Spontaneous Urticaria.
Primary Outcome
Safety of multiple, ascending doses of CDX-0159 as determined by drug related adverse events
Interventions
- DRUG Normal Saline
- DRUG CDX-0159
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-09-24 |
| Est. Completion | 2023-01-17 |
| Phase | Phase 1 |
What the finished NCT04538794 record still lists
NCT04538794 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 2 interventions - of which Normal Saline is the first listed.
NCT04538794 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04538794 about?
NCT04538794 is a clinical study titled "A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria". This is a study to determine the safety of multiple doses of CDX-0159 in patients with Chronic Spontaneous Urticaria.
What is the current status of trial NCT04538794?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2020-09-24. Estimated completion is 2023-01-17.
What interventions are being tested in trial NCT04538794?
The interventions under investigation include: Normal Saline (DRUG), CDX-0159 (DRUG).
Who is sponsoring clinical trial NCT04538794?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04538794's enrollment target sits among peer trials
45 1066th of 2000 higher than 915 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI